Head and Neck CancerSYNKNCT02385929
Pre-habilitation of Patients With Head and Neck Cancer
A study testing Swallowing therapy & resistance training in people with Head and Neck Cancer, run by Irene Wessel at 2 sites in Denmark.
Trial summary
The purpose of this study is to explore whether early initiated physical exercise concurrent with a swallowing and mouth opening exercise program will have a positive effect on swallowing function and other quality of life aspects in patients treated with radiotherapy for head and neck cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Head and Neck Cancer
- What is being tested?
- Swallowing therapy & resistance training
- Type of treatment
- Injection or infusion, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 240 participants
- Where
- 2 sitesDenmark
- Study dates
- 11 May 2015to Nov 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histological proven cancer in one or more of the following areas: larynx, hypopharynx, oropharynx, cavi oris, or unknown primary tumor
- Set to curative radiotherapy with or without concurrent chemotherapy for treatment of cancer in the head and neck region in accordance with the Danish Head and Neck Cancer Group (DAHANCA) guidelines
- Fully self-reliant
- Danish skills, oral and written
- Informed consent
Who cannot join
- Previously received treatment for head and neck cancer (radiotherapy, chemotherapy and/or surgery).
- Pregnancy
- ECOG performance status > 2
- Presence of psychological-, family-, sociological- or geographical issues that could prevent the patient from completing the intervention
- Simultaneous or previous illness or conditions that could prevent the patient's ability to complete the intervention.
Trial locations and contacts
2 sites in 1 country.
Denmark2 sites
Rigshospitalet
Copenhagen, 2100
Næstved Sygehus
Næstved, Region Sjælland, 4700
About this study
Official title: Bimodal Pre-habilitation Program to Improve Symptom Control After Treatment for Head and Neck Cancer
The purpose of this study is to explore whether early initiated physical exercise concurrent with a swallowing and mouth opening exercise program will have a positive effect on swallowing function and other quality of life aspects in patients treated with radiotherapy for head and neck cancer. The investigators hypothesize that patients who complete the program will have improved swallowing function and physical function one year after completing their treatment compared to patients who do not participate in the training program.
Read the detailed description
Although the potential negative impact of head and neck cancer (HNC) and its treatment on eating ability and quality of life is well documented there is no evidence based and standardized rehabilitation program available for Danish patients affected by HNC while going through radiotherapy (with or without concurrent chemotherapy). This study proposal is based on a thorough literature review on HNC treatment and late effects, and interventions targeting dysphagia and physical functioning.
Traditionally, rehabilitation is initiated when loss of function is already established. Emerging evidence suggests, however, that it can be of benefit to the patient to initiate an early rehabilitation process (prehabilitation) starting before initiation of treatment and during treatment. Prehabilitation aims to enhance pre-treatment functional capacity for better tolerance of treatment, facilitate general recovery, and prevent development of functional impairment or reduce the extent of these problems in a long-term perspective. HNC patients have a unique set of functional challenges such as pre- and post-treatment dysphagia, pain, and weight loss and often also high baseline levels of alcohol and tobacco consumption. In addition, studies have shown that only 31 % and 9 % of HNC patients are meeting public health guidelines for physical activity before and after diagnosis, respectively, and that weight loss in HNC patients treated with chemoradiation begin after only 1 week of therapy. Most of the weight loss was lean body mass (LBM) rather than fat loss. Loss of LBM is significantly associated with physical performance and increased functional dependence. The level of physical activity typically decreases significantly during treatment.
Dysphagia is considered the most prominent complication to HNC and its treatment, affecting physical function and quality of life. Post treatment dysphagia occurs in a significant proportion of patients and results from multiple factors such as xerostomia, taste loss, decreased sensory function, fibrosis and trismus. Disuse of swallowing muscles due to acute radiation effects or tube feeding can contribute to decline in swallowing function. Often, difficulties in swallowing and mouth opening are presenting features of HNC even at the time of diagnosis. To reduce these problems, patients may do a series of exercises before and during treatment to promote strength, mobility, and endurance of base of tongue, pharyngeal constrictors, and suprahyoid strap muscles. Although no definitive trials have yet been carried out, small randomized controlled trials (RCTs) and observational studies investigating pre-treatment swallowing and/or mouth opening exercise programs show promising benefits. Further, the few studies of resistance and cardio training on functional capacity in HNC patients are generally promising with medium to large effects on fatigue and physical function measures. For weight loss it seems as if progressive resistance training (PRT) is able to almost reverse the loss of LBM in HNC patients.
Generally studies on swallowing therapy for HNC patients have relied greatly on self-practice, and thus report low compliance. In view of this knowledge the investigators determine that there is a need for studies that include patients with HNC undergoing (chemo)radiation therapy focusing on i) prevention of dysphagia and loss of muscle strength and ii) improvement of compliance to mouth opening and swallowing exercises.
The purpose of the SYNK study is a randomized design to test the effect of theory based intervention on eating dysfunctions secondary to radiation treatment for HNC. The SYNK intervention consists of: i) individual instructions in swallowing and mouth opening exercises 3 days per week by occupational therapist throughout radiotherapy, ii) progressive resistance training twice weekly by physiotherapist, either individually or group based, throughout radiotherapy, iii) daily home-based swallowing and mouth opening exercises from beginning of treatment until 2 months after end-of-treatment (self-practice), and iv) weekly follow-up phone contacts with occupational therapists from end-of-treatment and 2 months onwards.
The investigators will enroll patients from the Oncological Department Rigshospitalet and randomize 240 patients. Patients will be randomized (1:1) to standard care plus the SYNK intervention and to standard care (control group).
The proposed study has the potential to support the general health status of HNC patients as well as to minimize adverse late effects of treatment (i.e. swallowing and mouth opening difficulties, general physical deterioration due to physical inactivity and problems with eating, and reduced QoL). The design of the intervention, being early, intensive and bimodal adds a new dimension to research in the prevention of devastating late effects in this particularly vulnerable patient group.
The investigators hypothesize that the SYNK intervention will:
- Improve swallowing function
- Improve physical function to stop the loss of muscle strength
- Improve quality of life and lessen the symptoms of anxiety and depression
- Conditions
- Head and Neck Cancer
- Being tested
- Swallowing therapy & resistance training
- Keywords
- Head and Neck Cancer, Intervention, Rehabilitation, Late Effects, Dysphagia
- Medical subject headings
- Head and Neck Neoplasms, Deglutition Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Swallowing therapy & resistance trainingBehavioural
- Individual instructions in swallowing and mouth opening exercises 3 days per week by occupational therapist throughout radiotherapy, ii) Progressive resistance training twice weekly by physiotherapist, either individually or group based, throughout radiotherapy, iii) Daily home-based swallowing and mouth opening exercises from beginning of treatment until 2 months after end-of-treatment. iv) Weekly follow-up phone contacts with occupational therapists from end-of-treatment and 2 months onwards.
| Study group | Role | What they receive |
|---|---|---|
| Swallowing therapy & resistance training | Experimental | Mouth opening and swallowing exercise intervention by occupational therapist for half an hour 3 times a week for 5-6 weeks during radiotherapy.
Progressive resistance training by physiotherapist for 1 hour twice weekly for 5-6 weeks during radiotherapy. Receives: Behavioral: Swallowing therapy & resistance training |
| Standard Care | No intervention | Patients in this arm are randomized to usual care / control group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Swallowing function measured by penetration aspiration scale (PAS) during a Fiber Endoscopic Evaluation of Swallowing (FEES).
To investigate the change in swallowing function among patients in intervention- and the control group from baseline to 14 and 58 weeks follow up and the difference in change between intervention - and the control group.
Measured: Baseline, 14 weeks and 58 weeks. Participants will be followed up till 12 months after they finalize their radiotherapy, an expected average of 58 weeks from baseline.
Secondary outcomes (12)
Level of fatigue by the EORCT QLQ-C30 3-point fatigue subscale.
To investigate the change in fatigue among patients in intervention- and the control group from baseline to 6,14, 28 and 58 weeks follow up and the difference in change between intervention - and the control group.
Measured: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Maximal Interincisal Distance (MID) by Therabite Range of Motion (ROM) scale
To investigate the change in mouth opening and the development of trismus (defined as MID ≤ 35mm) among patients in intervention- and the control group from baseline to 6,14, 28 and 58 weeks follow up and the difference in change between intervention - and the control group.
Measured: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Dysphagia related quality of life by M.D. Anderson Dysphagia Inventory (MDADI)
To investigate the change in patient reported quality of life related to dysphagia among patients in intervention- and the control group from baseline to 6, 14, 28 and 58 weeks follow up and the difference in change between intervention - and the control group. We will also use this outcome to evaluate correlation or deviations in patient vs observer rated outcomes by comparing the MDADI to the PAS score (primary outcome).
Measured: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Health related quality of Life by the European Organisation for Research and Treatment of Cancer (EORCT) Quality if Life Questionnaire (QLQ)-30 and EORCT QLQ - H&N35
To investigate the change in health related quality of life among patients in intervention- and the control group from baseline to 6,14, 28 and 58 weeks follow up and the difference in change between intervention - and the control group.
Measured: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Level of oral intake by Functional Oral Intake Scale (FOIS)
To investigate the change in oral intake and tube dependency among patients in intervention- and the control group from baseline to 6,14, 28 and 58 weeks follow up and the difference in change between intervention - and the control group.
Measured: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Weight loss by body weight
To investigate the change in weight loss among patients in intervention- and the control group from baseline to 6,14, 28 and 58 weeks follow up and the difference in change between intervention - and the control group.
Measured: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Physical strength by 30 seconds Sit to Stand (STS) test.
To investigate the change in lower extremities' strength as an expression of the overall physical strength among patients in intervention- and the control group from baseline to 6,14, 28 and 58 weeks follow up and the difference in change between intervention - and the control group.
Measured: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Pain by numerical rating scale (NRS)
To investigate the change in pain among patients in intervention- and the control group from baseline to 6,14, 28 and 58 weeks follow up and the difference in change between intervention - and the control group.
Measured: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Depression by Major Depression Inventory (MDI)
To investigate the change in depressive symptoms among patients in intervention- and the control group from baseline to 6,14, 28 and 58 weeks follow up and the difference in change between intervention - and the control group.
Measured: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Anxiety by Symptom Check List (SCL-92) Anxiety subscale
To investigate the change in anxiety among patients in intervention- and the control group from baseline to 6,14, 28 and 58 weeks follow up and the difference in change between intervention - and the control group.
Measured: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Performance Status by Eastern Cooperative Oncology Group (ECOG) performance scale
To investigate the change in performance status among patients in intervention- and the control group from baseline to 6,14, 28 and 58 weeks follow up and the difference in change between intervention - and the control group.
Measured: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Subjective symptoms of dysphagia by Eating Assessment Tool (EAT-10)
EAT-10 is a questionnaire screening tool used to evaluate patient-experienced symptoms of dysphagia and measures the level of ten specific difficulties related to swallowing. We will measure this outcome at the same time as our primary outcome to analyze the correlation between the subjective and objective measures of oropharyngeal dysphagia.
Measured: Participants will be followed up till 12 months after they finalize their radiotherapy, an expected average of 58 weeks from baseline.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Mar 2015 (estimated)
- Study start11 May 2015
- Primary completionNov 2019
- Study completionNov 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Head and Neck CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 240 participants (actual)
Sponsor and investigators
- Lead sponsor
- Irene Wessel
- Sponsor type
- University, hospital or other
- Collaborators
- Danish Cancer Society, Danish Association of Occupational Therapist, Copenhagen University Hospital, Rigshospitalet, Danish Cancer Research Foundation
- Responsible party
- Sponsor-investigator, Irene Wessel, Copenhagen University Hospital, Rigshospitalet
- Investigators
- Sara F Hajdú, M.Sc, Principal investigator, Copenhagen University Hospital, RigshospitaletSusanne O Dalton, professor, Principal investigator, Danish Cancer SocietyChristoffer Johansen, professor, Principal investigator, Copenhagen University Hospital, RigshospitaletIrene Wessel, MD, phd, Principal investigator, Copenhagen University Hospital, Rigshospitalet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02385929
- Sponsor's protocol ID
- H-2-2014-074
- Other IDs
- R108-A6969-14-S31
- Acronym
- SYNK
- Status last verified
- Mar 2020
- First submitted
- 9 Feb 2015
- Last updated
- 27 Mar 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Hajdu SF, Wessel I, Johansen C, Kristensen CA, Kadkhoda ZT, Plaschke CC, Dalton SO. Swallowing therapy and progressive resistance training in head and neck cancer patients undergoing radiotherapy treatment: randomized control trial protocol and preliminary data. Acta Oncol. 2017 Feb;56(2):354-359. doi: 10.1080/0284186X.2016.1269193.
PubMed 28206871Hajdu SF, Plaschke CC, Johansen C, Dalton SO, Wessel I. Cross-Cultural Translation, Adaptation and Reliability of the Danish M. D. Andeson Dysphagia Inventory (MDADI) in Patients with Head and Neck Cancer. Dysphagia. 2017 Aug;32(4):472-479. doi: 10.1007/s00455-017-9785-3. Epub 2017 Mar 7.
PubMed 28271296Fredslund SV, Hogdal N, Christensen MB, Wessel I. Dysphagia training after head and neck cancer fails to follow legislation and national recommendations. Dan Med J. 2015 May;62(5):A5067.
PubMed 26050828Hajdu SF, Christensen MB, Kristensen MO, Wessel I, Johansen C, Dalton S. Adherence to preventive swallowing exercises for head and neck cancer patients undergoing (chemo)radiotherapy treatment. Acta Oncol. 2019 May;58(5):658-664. doi: 10.1080/0284186X.2018.1563715. Epub 2019 Jan 30.
PubMed 30698049
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bimodal Pre-habilitation Program to Improve Symptom Control After Treatment for Head and Neck Cancer
- ClinicalTrials.gov ID
- NCT02385929
- Acronym / sponsor ID
- SYNK / H-2-2014-074
- Conditions
- Head and Neck Cancer
- Keywords
- Head and Neck Cancer, Intervention, Rehabilitation, Late Effects, Dysphagia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 240 participants (actual)
- Lead sponsor
- Irene WesselUniversity, hospital or other
- Collaborators
- Danish Cancer Society, Danish Association of Occupational Therapist, Copenhagen University Hospital, Rigshospitalet, Danish Cancer Research Foundation
- Study start
- 11 May 2015 (actual)
- Primary completion
- Nov 2019 (actual)
- Study completion
- Nov 2019 (actual)
- First posted
- 11 Mar 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to explore whether early initiated physical exercise concurrent with a swallowing and mouth opening exercise program will have a positive effect on swallowing function and other quality of life aspects in patients treated with radiotherapy for head and neck cancer. The investigators hypothesize that patients who complete the program will have improved swallowing function and physical function one year after completing their treatment compared to patients who do not participate in the training program.
Detailed description
Although the potential negative impact of head and neck cancer (HNC) and its treatment on eating ability and quality of life is well documented there is no evidence based and standardized rehabilitation program available for Danish patients affected by HNC while going through radiotherapy (with or without concurrent chemotherapy). This study proposal is based on a thorough literature review on HNC treatment and late effects, and interventions targeting dysphagia and physical functioning.
Traditionally, rehabilitation is initiated when loss of function is already established. Emerging evidence suggests, however, that it can be of benefit to the patient to initiate an early rehabilitation process (prehabilitation) starting before initiation of treatment and during treatment. Prehabilitation aims to enhance pre-treatment functional capacity for better tolerance of treatment, facilitate general recovery, and prevent development of functional impairment or reduce the extent of these problems in a long-term perspective. HNC patients have a unique set of functional challenges such as pre- and post-treatment dysphagia, pain, and weight loss and often also high baseline levels of alcohol and tobacco consumption. In addition, studies have shown that only 31 % and 9 % of HNC patients are meeting public health guidelines for physical activity before and after diagnosis, respectively, and that weight loss in HNC patients treated with chemoradiation begin after only 1 week of therapy. Most of the weight loss was lean body mass (LBM) rather than fat loss. Loss of LBM is significantly associated with physical performance and increased functional dependence. The level of physical activity typically decreases significantly during treatment.
Dysphagia is considered the most prominent complication to HNC and its treatment, affecting physical function and quality of life. Post treatment dysphagia occurs in a significant proportion of patients and results from multiple factors such as xerostomia, taste loss, decreased sensory function, fibrosis and trismus. Disuse of swallowing muscles due to acute radiation effects or tube feeding can contribute to decline in swallowing function. Often, difficulties in swallowing and mouth opening are presenting features of HNC even at the time of diagnosis. To reduce these problems, patients may do a series of exercises before and during treatment to promote strength, mobility, and endurance of base of tongue, pharyngeal constrictors, and suprahyoid strap muscles. Although no definitive trials have yet been carried out, small randomized controlled trials (RCTs) and observational studies investigating pre-treatment swallowing and/or mouth opening exercise programs show promising benefits. Further, the few studies of resistance and cardio training on functional capacity in HNC patients are generally promising with medium to large effects on fatigue and physical function measures. For weight loss it seems as if progressive resistance training (PRT) is able to almost reverse the loss of LBM in HNC patients.
Generally studies on swallowing therapy for HNC patients have relied greatly on self-practice, and thus report low compliance. In view of this knowledge the investigators determine that there is a need for studies that include patients with HNC undergoing (chemo)radiation therapy focusing on i) prevention of dysphagia and loss of muscle strength and ii) improvement of compliance to mouth opening and swallowing exercises.
The purpose of the SYNK study is a randomized design to test the effect of theory based intervention on eating dysfunctions secondary to radiation treatment for HNC. The SYNK intervention consists of: i) individual instructions in swallowing and mouth opening exercises 3 days per week by occupational therapist throughout radiotherapy, ii) progressive resistance training twice weekly by physiotherapist, either individually or group based, throughout radiotherapy, iii) daily home-based swallowing and mouth opening exercises from beginning of treatment until 2 months after end-of-treatment (self-practice), and iv) weekly follow-up phone contacts with occupational therapists from end-of-treatment and 2 months onwards.
The investigators will enroll patients from the Oncological Department Rigshospitalet and randomize 240 patients. Patients will be randomized (1:1) to standard care plus the SYNK intervention and to standard care (control group).
The proposed study has the potential to support the general health status of HNC patients as well as to minimize adverse late effects of treatment (i.e. swallowing and mouth opening difficulties, general physical deterioration due to physical inactivity and problems with eating, and reduced QoL). The design of the intervention, being early, intensive and bimodal adds a new dimension to research in the prevention of devastating late effects in this particularly vulnerable patient group.
The investigators hypothesize that the SYNK intervention will:
- Improve swallowing function
- Improve physical function to stop the loss of muscle strength
- Improve quality of life and lessen the symptoms of anxiety and depression
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Swallowing therapy & resistance training | Experimental | Behavioral: Swallowing therapy & resistance trainingMouth opening and swallowing exercise intervention by occupational therapist for half an hour 3 times a week for 5-6 weeks during radiotherapy. Progressive resistance training by physiotherapist for 1 hour twice weekly for 5-6 weeks during radiotherapy. |
| Standard Care | No intervention | –Patients in this arm are randomized to usual care / control group |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Histological proven cancer in one or more of the following areas: larynx, hypopharynx, oropharynx, cavi oris, or unknown primary tumor
- Set to curative radiotherapy with or without concurrent chemotherapy for treatment of cancer in the head and neck region in accordance with the Danish Head and Neck Cancer Group (DAHANCA) guidelines
- Fully self-reliant
- Danish skills, oral and written
- Informed consent
Key exclusion criteria (5 listed)
- Previously received treatment for head and neck cancer (radiotherapy, chemotherapy and/or surgery).
- Pregnancy
- ECOG performance status > 2
- Presence of psychological-, family-, sociological- or geographical issues that could prevent the patient from completing the intervention
- Simultaneous or previous illness or conditions that could prevent the patient's ability to complete the intervention.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Swallowing therapy & resistance trainingi) Individual instructions in swallowing and mouth opening exercises 3 days per week by occupational therapist throughout radiotherapy, ii) Progressive resistance training twice weekly by physiotherapist, either individually or group based, throughout radiotherapy, iii) Daily home-based swallowing and mouth opening exercises from beginning of treatment until 2 months after end-of-treatment. iv) Weekly follow-up phone contacts with occupational therapists from end-of-treatment and 2 months onwards. | Behavioural | Swallowing therapy & resistance training |
Primary outcome
Swallowing function measured by penetration aspiration scale (PAS) during a Fiber Endoscopic Evaluation of Swallowing (FEES).
Time frame: Baseline, 14 weeks and 58 weeks. Participants will be followed up till 12 months after they finalize their radiotherapy, an expected average of 58 weeks from baseline.
To investigate the change in swallowing function among patients in intervention- and the control group from baseline to 14 and 58 weeks follow up and the difference in change between intervention - and the control group.
12 secondary outcomes
Level of fatigue by the EORCT QLQ-C30 3-point fatigue subscale.
Time frame: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Maximal Interincisal Distance (MID) by Therabite Range of Motion (ROM) scale
Time frame: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Dysphagia related quality of life by M.D. Anderson Dysphagia Inventory (MDADI)
Time frame: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Health related quality of Life by the European Organisation for Research and Treatment of Cancer (EORCT) Quality if Life Questionnaire (QLQ)-30 and EORCT QLQ - H&N35
Time frame: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Level of oral intake by Functional Oral Intake Scale (FOIS)
Time frame: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Weight loss by body weight
Time frame: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Physical strength by 30 seconds Sit to Stand (STS) test.
Time frame: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Pain by numerical rating scale (NRS)
Time frame: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Depression by Major Depression Inventory (MDI)
Time frame: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Anxiety by Symptom Check List (SCL-92) Anxiety subscale
Time frame: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Performance Status by Eastern Cooperative Oncology Group (ECOG) performance scale
Time frame: baseline, 6 weeks, 14 weeks, 28 weeks and 58 weeks.
Subjective symptoms of dysphagia by Eating Assessment Tool (EAT-10)
Time frame: Participants will be followed up till 12 months after they finalize their radiotherapy, an expected average of 58 weeks from baseline.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2020.
- Background: PubMed 28206871Hajdu SF, Wessel I, Johansen C, Kristensen CA, Kadkhoda ZT, Plaschke CC, Dalton SO. Swallowing therapy and progressive resistance training in head and neck cancer patients undergoing radiotherapy treatment: randomized control trial protocol and preliminary data. Acta Oncol. 2017 Feb;56(2):354-359. doi: 10.1080/0284186X.2016.1269193.
- Background: PubMed 28271296Hajdu SF, Plaschke CC, Johansen C, Dalton SO, Wessel I. Cross-Cultural Translation, Adaptation and Reliability of the Danish M. D. Andeson Dysphagia Inventory (MDADI) in Patients with Head and Neck Cancer. Dysphagia. 2017 Aug;32(4):472-479. doi: 10.1007/s00455-017-9785-3. Epub 2017 Mar 7.
- Background: PubMed 26050828Fredslund SV, Hogdal N, Christensen MB, Wessel I. Dysphagia training after head and neck cancer fails to follow legislation and national recommendations. Dan Med J. 2015 May;62(5):A5067.
- Derived from this study: PubMed 30698049Hajdu SF, Christensen MB, Kristensen MO, Wessel I, Johansen C, Dalton S. Adherence to preventive swallowing exercises for head and neck cancer patients undergoing (chemo)radiotherapy treatment. Acta Oncol. 2019 May;58(5):658-664. doi: 10.1080/0284186X.2018.1563715. Epub 2019 Jan 30.
- Individual participant dataSharing planned: No
Related trials for Head and Neck Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm Trial
Head & Neck Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 2
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sara F Hajdú, M.Sc principal investigator
Copenhagen University Hospital, Rigshospitalet
Susanne O Dalton, professor principal investigator
Danish Cancer Society
Christoffer Johansen, professor principal investigator
Copenhagen University Hospital, Rigshospitalet
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Swallowing therapy & resistance training in people with Head and Neck Cancer, run by Irene Wessel at 2 sites in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Mar 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Swallowing function measured by penetration aspiration scale (PAS) during a Fiber Endoscopic Evaluation of Swallowing (FEES). (time frame: Baseline, 14 weeks and 58 weeks. Participants will be followed up till 12 months after they finalize their radiotherapy, an expected average of 58 weeks from baseline.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02385929, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2020.